Tricyclic compounds useful in treating iron disorders

A technology of compounds and mixtures, applied in the field of divalent metal transporter-1 inhibitors, which can solve problems such as tissue damage and increased risk

Inactive Publication Date: 2009-12-30
XENON PHARMACEUTICALS INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Excess accumulation of iron can lead to significant tissue damage and increased risk of concurrent diseases such as cirrhosis or hepatocellular carcinoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tricyclic compounds useful in treating iron disorders
  • Tricyclic compounds useful in treating iron disorders
  • Tricyclic compounds useful in treating iron disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0114] Among the aspects of the invention set forth above in the Summary of the Invention, certain embodiments of these aspects are preferred.

[0115] One aspect of the present invention is the compound of general formula (I) as set forth in the Summary of the Invention above, its stereoisomers, enantiomers, tautomers or mixtures thereof; or its pharmaceutically acceptable salts, Solvates or Prodrugs.

[0116] One embodiment of this aspect are compounds of general formula (I) as set forth above in the Summary of the Invention, wherein:

[0117] n and m are each independently 0, 1 or 2;

[0118] R 1 with R 2 Each independently is a chemical bond, -C(R 9 ) 2 -, -S-, -O-, -C(O)-, -N(R 9 )-or-CH 2 -R 10 -CH 2 -;

[0119] R 3 with R 4 same, and selected from -R 11 -S-C(=NR 12 )N(R 12 )R 13 ,-R 11 -O-C(=NR 12 )N(R 12 )R 13 ,-R 11 -C(=NR 12 )N(R 12 )R 13 or -R 11 -N(R 9 )-C(=NR 12 )N(R 12 )R 13 ;

[0120] R 5 with R 6 Same, and selected from hydrogen,...

Embodiment 1

[0836] Synthesis of dibenzo[b,d]thiophene-4,6-diylbis(methylene)diisothiourea dihydrobromide

[0837]

[0838]To a solution of 4,6-bis(bromomethyl)dibenzo[b,d]thiophene (0.19 g, 0.50 mmol) in ethanol (10 mL) was added thiourea (0.076 g, 1.0 mmol) . The mixture was maintained at 80°C for 14 hours and cooled to ambient temperature. Ethanol was removed to one-third of the original volume, and hexane was added. The precipitated solid was collected by filtration, washed with ether and ethyl acetate, and dried in air to give dibenzo[b,d]thiophene-4,6-diylbis(methylene)diisothiourea Dihydrobromide, yield 84% (0.22 g): 1 H NMR (300MHz, DMSO-d 6 )δ9.34 (brs, 4H), 9.13 (brs, 4H), 8.40 (d, J=7.7Hz, 2H), 7.64 (d, J=7.7Hz, 2H), 7.57 (dd, J=7.7, 7.7Hz, 2H), 4.81(s, 4H); 13 C NMR (75MHz, DMSO-d 6 ) δ 169.3, 138.3, 136.6, 129.1, 128.9, 126.3, 123.0, 34.5; MS (ES+) m / z 361.1 (M+1).

Embodiment 11

[0840] Synthesis of (3,7-dibromodibenzo[b,d]thiophene-4,6-diyl)bis(methylene)diisothiourea dihydrobromide

[0841]

[0842] Following the procedure as described in Example 1, with non-critical changes, 3,7-dibromo-4,6-bis(bromomethyl)dibenzo[b,d]thiophene was used instead of 4,6- Bis(bromomethyl)dibenzo[b,d]thiophene to obtain (3,7-dibromodibenzo[b,d]thiophene-4,6-diyl)bis(methylene)diisosulfur Urea dihydrobromide, a colorless solid, yield 85%: melting point > 220°C; 1 H NMR (300MHz, DMSO-d 6 )δ9.62-9.16 (br s, 8H), 8.37 (d, J = 8.4Hz, 2H), 7.89 (d, J = 8.4Hz, 2H), 4.90 (s, 4H); 13 C NMR (75MHz, DMSO-d 6 ) δ 169.4, 140.8, 135.5, 131.0, 127.0, 125.0, 124.2, 36.0; MS (ES+) m / z 517.1 (M+1), 519.1 (M+1), 521.1 (M+1).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

This invention is directed to, for example, compounds of formula (I): wherein n, m, R<1>, R<2>, R<3>, R<4>, R<5>, R<6>, R<7> and R<8> are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment of iron disorders. This invention is also directed to pharmaceutical compositions comprising the compounds and methods of using the compounds to treat iron disorders.

Description

field of invention [0001] The present invention relates to tricyclic compounds which are divalent metal transporter-1 inhibitors. Accordingly, the compounds of the present invention and pharmaceutical compositions comprising the same are useful in the treatment of iron disorders in mammals. Background of the invention [0002] Iron is an essential metal for life as it is a major component of a family of essential proteins including hemoglobin, cytochrome and NADH-CoQ reductase. Maintaining the body's iron homeostasis is critical to health because iron deficiency or excess can lead to morbidity and death. [0003] Divalent metal transporter-1 (DMT1), also known as natural resistance-associated macrophage protein-2 (NRAMP2) and divalent cation transporter-1 (DCT1), is ubiquitously expressed in vivo and involved in maintaining iron levels of transmembrane proteins. DMT1 is particularly important for the absorption of iron in the duodenum of the small intestine, where DMT1 is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): C07C321/20C07D219/02C07D307/91C07D311/82C07D333/50C07D337/10A61K31/155A61P7/00
CPCC07D307/91C07C2103/24C07C2103/08C07D337/10C07D327/08C07D219/02C07D333/50C07D311/82C07C335/32C07C2103/18A61P3/02A61P3/12A61P7/00A61P7/06A61P43/00C07C2603/08C07C2603/18C07C2603/24
Inventor麦克海里·乔威夫纳加斯瑞·柴卡琼-杰克库·卡迪厄傅健民拉金德·坎博日维什努墨西·库德穆鲁乔纳森·朗吉乐刘世峰孙建宇塞尔戈·斯维里多夫张载辉
OwnerXENON PHARMACEUTICALS INC